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Abstract
Introduction: Statins reduce risk of cardiovascular events and have beneficial pleiotropic effects; both may reduce
mortality in critically ill patients. We examined whether statin use was associated with risk of death in general
intensive care unit (ICU) patients.
Methods: Cohort study of 12,483 critically ill patients > 45 yrs of age with a first-time admission to one of three
highly specialized ICUs within the Aarhus University Hospital network, Denmark, between 2001 and 2007. Statin
users were identified through population-based prescription databases. We computed cumulative mortality rates
0-30 days and 31-365 days after ICU admission and mortality rate ratios (MRRs), using Cox regression analysis
controlling for potential confounding factors (demographics, use of other cardiovascular drugs, comorbidity,
markers of social status, diagnosis, and surgery).
Results: 1882 (14.3%) ICU patients were current statin users. Statin users had a reduced risk of death within 30
days of ICU admission [users: 22.1% vs. non-users 25.0%; adjusted MRR = 0.76 (95% confidence interval (CI): 0.69 to
0.86)]. Statin users also had a reduced risk of death within one year after admission to the ICU [users: 36.4% vs.
non-users 39.9%; adjusted MRR = 0.79 (95% CI: 0.73 to 0.86)]. Reduced risk of death associated with current statin
use remained robust in various subanalyses and in an analysis using propensity score matching. Former use of
statins and current use of non-statin lipid-lowering drugs were not associated with reduced risk of death.
Conclusions: Preadmission statin use was associated with reduced risk of death following intensive care. The
associations seen could be a pharmacological effect of statins, but unmeasured differences in characteristics of
statin users and non-users cannot be entirely ruled out.
Introduction
There is substantial evidence that statins - widely used
lipid-lowering drugs - are effective in reducing major car-
diovascular events and mortality in patients with arterio-
sclerotic disease, diabetes and hypercholesterolemia
[1-4]. Experimental studies reported evidence that statins
may also have anti-inflammatory, anti-thrombotic and
immuno-modulating effects independent of lowering lipids,
also referred to as pleiotropic properties [5,6]. The pleiotro-
pic properties may differ between individual statins, in par-
ticular between lipophilic and hydrophilic statins [7-9].
In line with the experimental findings, observational
studies have reported a risk reduction [10-12] and
profound improvements in the outcome of critical ill-
nesses such as severe infections among statin users
[13-17]. Beneficial effects in terms of reduced morbidity
and mortality of statins have also been reported among
patients with chronic obstructive pulmonary disease,
chronic renal failure and in patients undergoing cardiac
or major non-cardiac surgery [18-21].
Patients in intensive careu n i t s( I C U s )h a v eah i g h
prevalence of cardiovascular diseases, severe infections
and thrombotic complications, and almost all ICU
patients suffer from the systemic inflammatory response
syndrome [22,23]. Statins could thus have beneficial
effects on mortality following ICU admission. The three
existing studies on this issue reported conflicting results
and were limited by small and highly selected study
populations such as patients with multiple organ dys-
function syndrome or acute lung injury/adult respiratory
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only while in the hospital [24-26]. As intensive care
treatment is common, expensive and often ends in
death, any beneficial effect of statins in this setting has
major clinical and public health implications.
We conducted a large cohort study, based on more
than 12,000 ICU patients, to examine the extent to
which preadmission statin use overall and by specific
agent was associated with risk of death in the year fol-
lowing ICU admission.
Materials and methods
Setting
We conducted this cohort study based on prospectively
collected data obtained from medical databases in north-
ern Denmark between 1 January, 2001 and 31 December,
2007. The Danish national health care system provides
the entire Danish population with unrestricted access to
tax-supported public health services and all critically ill
patients receive care in public hospitals [27].
Since 1968 every Danish citizen has received at birth a
unique civil registration number from the Danish Civil
Registration System. This number permits accurate link-
age across all Danish registries [28].
The study population comprised all patients admitted
for the first time to an ICU in one of three hospitals
within the Aarhus University Hospital network (Aalborg,
Aarhus and Skejby Hospitals) [29]. All ICUs are highly
specialized multidisciplinaryu n i t ss e r v i n gb o t ha sp r i -
mary and referral ICUs. Their patients include those
with severe respiratory failure requiring extracorporeal
membrane oxygenation and patients undergoing organ
transplantation.
Intensive care data
ICU patients were identified using a research database
(Aarhus University Intensive Care Cohort (AUICC)).
Data on use of mechanical ventilation, use of renal
replacement therapy, dates of ICU admission and dis-
charge, and civil registration numbers for all patients
treated in the three ICUs are recorded by ICU physi-
cians as part of standard department clinical practice
and are routinely entered into the AUICC. We did not
include in the cohort patients who were admitted for
planned postoperative observation of less than 24 hours
and did not include patients younger than 45 years of
age, a group that is rarely prescribed statins [30]. The
study cohort totaled 12,483 eligible ICU patients with a
first ICU admission during the study period.
Preadmission use of statins
We used a prescription database covering the entire
region since 1998 to identify statin users. The database
contain data, transferred electronically from all
pharmacies in the region, on types and dosages of all
reimbursed drugs prescribed, customers’ civil registra-
tion numbers and redemption dates [31]. We defined
current statin use as at least one filled prescription for
statins within 125 days before ICU admission (for details
on Anatomical Therapeutic Chemical (ATC) codes see
Additional file 1) [31]. The 125-day period allowed us to
capture most current statin users, because in Denmark
few statin prescriptions are expected to last more than
125 days [17,30]. Among current statin users, we distin-
guished ‘new’ and ‘long-term’ statin users as those who
had filled their first statin prescription within 125 days
before ICU admission or earlier than 125 days, respec-
tively [32].
Statin users may have been more frequently hospita-
lized during the exposure defining period before ICU
admission than non-users. As no prescriptions are filled
during hospitalizations this may lead to misclassification
of statin use [33]. We therefore used the Danish
National Registry of Patients (NRP) to identify the num-
ber of days that study patients were hospitalized within
the 125 days before ICU admission (0 days, 1 to 10
days,11 to 25 days, >25 days).
Other prognostic factors
We identified the main diagnosis for the admission
requiring intensive care through the Danish NRP. The
NRP covers all hospitalizations in Denmark since 1977
and all out-patient hospital visits since 1995 [34]. We
grouped patients into eight disease categories: infectious
diseases; endocrinology including diabetes; cardiovascu-
lar diseases; respiratory diseases; gastrointestinal and
liver diseases; cancer; trauma and poisoning; and others
(for details on International Classification of Diseases
(ICD) codes, see Additional file 1). We also identified
the department that transferred the patient to the ICU
(surgical/medical). Using the NRP, we obtained informa-
tion on surgical procedures in the seven days before
ICU admission and classified patients as surgical and
medical (no surgery within seven days before ICU
admission) [35]. To control for comorbidity, we com-
puted the Charlson comorbidity score based on the
entire previous discharge history and defined three
comorbidity levels: low (score of 0), medium (1 to 2),
and high (≥ 3)) [36]. The index includes 19 major dis-
ease categories and has been validated as a predictor of
mortality [37,38]. We also retrieved information on alco-
holism-related disorders, and prescriptions for disulfiram
(ICD and ATC codes are provided in Additional file 1).
For the subcohort of patients admitted between 2001
and 2006 we collected data on hemoglobin, white blood
cell (WBC) count, platelets, C-reactive protein (CRP)
and bilirubin on ICU admission and on the most recent
total cholesterol level recorded within six months of
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prescription data on current use of angiotensin convert-
ing enzymes (ACE) inhibitors, beta blockers, and low-
dose aspirin, because these drugs may confound studies
on clinical effects of statins [18,39], and on current use
of non-statin lipid-lowering drugs, because these drugs
are given on almost the same indications as statins but
lack the pleiotropic effects (e.g. niacin, bile acid-binding
resin and fibric acid derivatives). As a measure of social
status, we obtained data on marital status at the time of
ICU admission from the Civil Registration System [28].
Mortality data
We accessed data from the Civil Registration System,
which contains complete information for the entire
Danish population on migration and changes in vital
status, including exact date of death, and is updated on
a daily basis [28].
Statistical analysis
Follow up began on the date of first-time ICU admission
and continued until death, migration, 365 days after ICU
admission or 31 December 2008, whichever came first.
We computed Kaplan Meier curves and life table esti-
mates for mortality at 30 days and one year for the fol-
lowing variables: preadmission statin use; primary
diagnosis; age group; gender; department (medical/surgi-
cal); level of Charlson score; alcoholism-related diseases;
surgery within seven days (yes/no); need for mechanical
ventilation or renal replacement therapy; current use of
ACE inhibitors, low-dose aspirin or beta blockers; mari-
tal status (married, divorced, widowed, never married, or
unknown).
We used Cox proportional hazards regression to com-
pute mortality rate ratios (MRRs) for statin users com-
pared with non-users, controlling for all covariates in
Tables 1 and 2, except mechanical ventilation, dialysis,
and laboratory data because we considered these poten-
tial effects of the intervention [40]. We did separate ana-
lyses for subgroups defined according to admitting
department, surgery, presence of mechanical ventilation,
renal replacement therapy, and for former, new, and
long-term statin users. As the pleiotropic effects may
vary between types of statins we also did a separate ana-
lysis for users of the lipophilic simvastatin, and the
hydrophilic atorvastatin and pravastatin and used Wald
statistics to compute P values for the difference in MRR
between types of statins.
To assess possible unmeasured confounding by indica-
tion for statin treatment we restricted the analysis to
patients with a previous diagnosis of ischemic or unspe-
cified stroke, atherosclerosis, ischemic heart disease or
diabetes mellitus. We also repeated the analysis after
excluding patients with cancer and for users of non-
statin lipid-lowering agents. Details on ICD codes are
provided in Additional file 1.
To further control for confounding we conducted a
supplementary analysis using propensity score matching
[41,42]. We generated a multivariable logistic regression
model that predicted statin use among ICU patients
based on the covariate profile listed in Tables 1 and 2,
except laboratory data and mechanical ventilation and
dialysis, and computed the propensity score for all ICU
patients. We then matched each statin user with one
non-user using a greedy matching algorithm. All statin
users could be matched to a non-user. Propensity score
Table 1 Baseline characteristics by preadmission statin
use among 12,483 ICU patients, Aarhus University
Hospital, Denmark 2001 to 2007
Statin use
n (%)
No statin use
n (%)
Overall 1882 (14.3%) 10,601 (85.7%)
Age group (years)
45-60 373 (19.8%) 3725 (35.1%)
61-75 1095 (58.2%) 4421 (41.7%)
76+ 414 (22.0%) 2455 (23.2%)
Gender
Male 1193 (63.4%) 6085 (57.4%)
Female 689 (36.6%) 4516 (42.6%)
Comorbidity score*
Low 283 (15.0%) 3563 (33.6%)
Medium 862 (45.8%) 4280 (40.4%)
High 737 (39.2%) 2758 (26.0%)
Comorbidity diagnosis**
Ischemic heart disease 658 (35.0%) 950 (9.0%)
Congestive heart failure 406 (21.6%) 1113 (10.5%)
Peripheral vascular disease 451 (24.0%) 1050 (9.9%)
Cerebrovascular disease 468 (24.9%) 1393 (13.1%)
COPD 339 (18.0%) 1836 (17.3%)
Diabetes 456 (24.2%) 879 (8.3%)
Cancer 299 (15.9%) 2401 (22.5%)
Renal disease 171 (9.0%) 586 (5.4%)
Alcoholism-related diseases 137 (7.3%) 1305 (12.3%)
Cardiovascular drug use
ACE inhibitors 1003 (53.3%) 1860 (17.6%)
Beta blockers 983 (52.2%) 1706 (16.1%)
Low-dose aspirin 336 (17.9%) 674 (6.4%)
Marital status
Married 1141 (60.6%) 5664 (53.4%)
Divorced 251 (13.3%) 1512 (14.3%)
Widowed 345 (18.3%) 2033 (19.2%)
Never married 139 (7.4%) 1135 (10.7%)
Unknown 6 (0.3%) 257 (2.4%)
*Level of Charlson comorbidity index.
**Patients may have more than one comorbidity.
ACE: angiotensin converting enzyme; COPD: chronic obstructive pulmonary
disease; ICU: intensive care unit.
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ences of each covariate to values below 0.1 indicating
that an adequate balance was achieved. We then used
Cox regression analysis to compute 30-day and one-year
MRR in the matched cohort.
The assumptions of proportional hazards in all Cox
regression models were assessed graphically and found
to be appropriate. All analyses were performed using
SAS version 9.2 (SAS Institute Inc, Cary, NC, USA).
The study was approved by the Danish Data Protec-
tion Agency (record number 2005-41-4782) and the
Aarhus University Hospital Registry Board. Data were
obtained from Danish registries, which are generally
available to researchers and their use does not require
informed consent.
Results
Descriptive data
We identified 12,483 first-time ICU patients older than
45 years. Of these, 1,882 (15.1%) were current statin
users on admission (Table 1). Simvastatin was by far the
most used statin (1391, 73.9%), followed by atorvastin
(240, 12.8%), pravastatin (170, 9.0%) and other statins
(81, 4.3%). Statin users were more likely to be male, and
have higher levels of comorbidity than other ICU
patients. Diabetes and cardiovascular diseases were, as
expected, more prevalent among statin users than
among non-users, whereas cancer and alcoholism-
r e l a t e dd i s e a s e sw e r el e s sc o m m o n .S t a t i nu s e r sw e r e
more frequently users of ACE inhibitors, beta blockers
or low-dose aspirin than non-users (Table 2). At ICU
admission, statin users had higher average blood levels
of creatinine, similar WBC count and slightly lower
levels of CRP than non-users.
A total of 151 (8.0%) statin users and 917 (8.7%) non-
users were hospitalized for more than 25 days during
the 125 days before ICU admission.
30-day mortality
Throughout the follow-up period, statin users had con-
siderably lower risk of death than statin non-users
(Figure 1). The risk of death within 30 days after ICU
Table 2 Characteristics associated with the current hospitalization of 12,483 ICU patients with and without
preadmission statin use, Aarhus University Hospital, Denmark, 2001 to 2007
Statin use
n (%)
No statin use
n (%)
Department
Medical 771 (41.0%) 4243 (40.0%)
Surgical 1111 (59.0%) 6358 (60.0%)
Main diagnosis
Infections 43 (2.3%) 253 (2.4%)
Cancer 163 (8.7%) 1607 (15.2%)
Diabetes 30 (1.6%) 129 (1.2%)
Cardiovascular 800 (42.5%) 2828 (26.7%)
Respiratory 132 (7.0%) 1049 (9.9%)
Gastrointestinal 163 (8.7%) 1187 (11.2%)
Trauma/poisoning 136 (7.2%) 1383 (13.1%)
Other 415 (22.0%) 2165 (20.4%)
Surgical status at ICU admission
Surgery within 7 days 199 (10.6%) 1347 (12.7%)
Mechanical ventilation 1021 (54.3%) 4796 (45.3%)
Renal replacement therapy 223 (11.9%) 867 (8.2%)
Laboratory findings, median (IQR)*
Hemoglobin (ref; female: 7.4-9.6 mmol/l, male:8.4-10.8 mmol/l) 7.10 (6.30-8.20) 7.30 (6.40-8.30)
Creatinine (ref 60-125 μmol/l) 106.5 (80-165) 93 (70-138)
Bilirubin (ref 4-21 mmol/l) 10 (7-16) 12 (8-20)
C-reactive protein (ref <10 mg/l) 80 (15-250) 97 (21-279)
White blood cell count
(ref 4.0-11.0 × 10
9/l)
12.2 (8.8-16.0) 12.3 (9.0-16.7)
Total cholesterol (ref 3.0-6.7 mmol/l) 4.6 (3.9-5.5) 5.0 (4.1-5.9)
*For the subcohort of patients admitted between 2001 and 2006. Highest test result on day of intensive care unit (ICU) admission or the following day for
creatinine, bilirubin C-reactive protein and white blood cell count and the lowest test results for hemoglobin. For cholesterol closets record value within one year
before ICU admission.
IQR: interquartile range.
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among non-users, corresponding to a crude MRR of 0.85
(95% confidence interval (CI) = 0.76 to 0.96; Table 3).
After control for potential confounders the 30-day MRR
was 0.76 (95% CI = 0.68 to 0.85). For all diagnostic cate-
gories, except diabetes and infectious diseases, statin use
was associated with a reduced risk of death (Figure 2).
The MRRs seemed lower for users of simvastatin
(MRR = 0.74, 95% CI = 0.65 to 0.84) than for other types
of statins (atorvastatin MRR = 0.95, 95% CI = 0.72 to
1.25; pravastatin MRR = 0.96, 95% CI = 0.71 to 1.30);
however, the differences were not statistically significant
(P = 0.42).
Exclusion of patients with cancer from the analysis or
restriction to patients with cardiovascular diseases or
diabetes left the decreased MRRs for statins virtually
unchanged. Of note the risk of death seemed not to be
reduced by non-statin lipid-lowering drug use (MRR =
1.29, 95% CI = 0.80 to 2.08) or by former statin use
(MRR = 0.88, 95% CI = 0.73 to 1.06). For new and long-
term statin users the adjusted MRRs were 0.68 (95% CI =
0.51 to 0.90) and 0.81 (95% CI = 0.72 to 0.91),
respectively.
Further stratified analyses showed an adjusted 30-day
MRR of 0.81 (95% CI = 0.67 to 0.97) among ICU
patients who had surgery within seven days of ICU
admission, and 0.76 (95% CI = 0.66 to 0.87) among
ICU patients who had no surgery within seven days.
The propensity score matched analysis yielded a MRR
similar to the estimates from the conventional Cox
regression analysis (adjusted MRR = 0.71, 95% CI = 0.61
to 0.83).
One-year mortality
The one-year risk of death was 36.4% among statin
users compared with 39.9% among non-users; crude
MRR was 0.84 (95% CI = 0.76 to 0.93) decreasing to
0.79 (95% CI = 0.73 to 0.87) after controlling for con-
founding factors. The one-year reduction in risk of
death remained robust in all diagnostic categories and
seemed most pronounced for simvastatin (simvastatin
MRR = 0.77, 95% CI = 0.70 to 0.85; atorvastatin MRR =
Figure 1 One-year survival curve of 1881 statin users and 10,601 non-users. ICU, intensive care unit.
Table 3 Cumulative 0 to 30 and 31 to 365 day mortality
and corresponding crude and adjusted mortality rate
ratios (MRR)
Number
(n)
Mortality
(%)
Crude MRR
(95% CI)
Adjusted MRR
(95% CI)*
0 to 30 days
Statin use 1882 22.1% 0.85 (0.76-0.96) 0.76 (0.68-0.85)
No statin use 11,313 25.0% 1 – 1 –
0 to 365 days
Statin use 1882 36.4% 0.84 (0.76-0.93) 0.78 (0.71-0.84)
No statin use 11,313 39.9% 1 – 1 –
*Adjusted by Cox proportional hazards for age group, gender, medical/
surgical department, diagnosis, Charlson index score and alcoholism-related
disease, surgery within seven days, current use of angiotensin converting
enzyme inhibitors, beta blockers and low-dose aspirin and marital status.
CI: confidence interval.
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95% CI = 0.81 to 1.31); however, the difference between
statins did not reach statistical significance (P =0 . 3 5 ) .
The reduction in risk of death associated with statin use
remained virtually unchanged when analyses were
restricted to patients without cancer or to patients with
cardiovascular disease or diabetes (Figure 3). MRR
among new and long-term statin users were 0.80 (95%
CI = 0.65 to 0.98) and 0.81 (95% CI = 0.74 to 0.89),
respectively. Former statin use and use of non-statin
lipid-lowering drugs was not to be associated with
reduced risk of death within one year of ICU admission.
The propensity score matched analysis yielded an
adjusted MRR of 0.70 (95% CI = 0.62 to 0.80).
Discussion
In this large cohort study we found that preadmission
statin use was associated with considerably reduced risk
of death among ICU patients. The reduced risk of death
remained robust in various subgroup analyses, including
among new and long-term statin users. We found no
clear association between former statin use and non-sta-
tin lipid-lowering drug use and risk of death, which sup-
ports a causal association between statin use and
reduced risk of death among ICU patients.
Existing studies
Increasing evidence exists that statins may reduce mor-
tality in patients with severe infections including sepsis
[13-17] but limited and conflicting data exist on the
association between statin use and in-hospital/30-day
mortality among general ICU patients. In a 2006 Ger-
man cohort study of 120 ICU patients with multiple
organ dysfunction syndrome, Schmidt and colleagues
reported that statin use was associated with substantially
reduced in-hospital mortality (MRR = 0.53, 95% CI =
0.29 to 0.99), a result consistent with our findings [25].
Also in line with our findings, a recent US study among
178 patients with ALI/ARDS found reduced ICU and
in-hospital mortality among statin users (odds ratio
Figure 2 Adjusted 30-day MRRs comparing preadmission statin use with non-use overall and within different patient subgroups.
N denotes the number of patients included in the analysis. CI, confidence interval; MMR, mortality rate ratios.
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for in-hospital mortality 0.62, 95% CI = 0.29 to 1.32);
however, the relatively small study population hindered
a clear interpretation of the risk estimates [26]. In con-
trast, a 2006 Spanish observational study of 438 patients
mechanically ventilated for more than 96 hours reported
higher in-hospital mortality among statin users (61%)
than non-users (42%; OR = 2.30, 95% CI = 1.08 to 4.89)
[24]. All studies included highly selected subgroups of
ICU patients and did not adjust for important covariates
such as comorbidity and use of other cardiovascular
drugs. To our knowledge, no former data exist on the
effect of statins on long-term risk of death among ICU
patients.
The biological mechanisms underlying our observa-
tions are not yet entirely understood. However, the high
prevalence of systemic inflammatory response syndrome
and/or severe infections among ICU patients may
increase the risk of fatal venous and arterial thrombotic
events by inducing endothelial dysfunction and
atherosclerotic plaque instability [43-45]. There is strong
experimental evidence that statins have beneficial effects
on platelet function, coagulation, fibrinolysis, and plaque
formation, as well as inhibitory effects on endothelial
dysfunction [46-50]. Also, statins have immuno-modu-
lating effects that may be beneficial during the initial
‘hyper-immune’ phase of critical illness [5,23]. Differ-
ences in these pleiotropic properties between lipophilic
and hydrophilic statins may explain the possible differ-
ences between individual statins suggested by our data,
although these differences were not statistically signifi-
cant [7-9]. One randomized controlled trial including 82
patients with acute bacterial infections confirmed that
statins reduce the levels of inflammatory cytokines [51].
Limitations
We conducted this study within a tax-financed national
health service system with free access to health care,
which largely removed referral bias. We had complete
and independently collected data on preadmission statin
Figure 3 Adjusted one-year MRRs comparing preadmission statin use with non-use overall and within different patient subgroups.
N denotes the number of patients included in the analysis. CI, confidence interval; MMR, mortality rate ratios.
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information and surveillance bias. The relatively large
number of ICU patients enabled robust analysis on sev-
eral ICU subgroups showing consistent results.
The validity of our findings depends ultimately on
accurate registration of statin use and the ability to con-
trol for confounding. The completeness and nature of
the prescription database used makes the measurement
of filled prescriptions for statins highly valid [31]. In
Denmark, adherence to statin therapy is high, and any
influence of non-compliance should therefore be minor,
potentially attenuating our mortality estimates towards
unity [52]. As few statin users were hospitalized for
more than 25 days during the 125 days before ICU
admission, misclassification of statin use because of
more frequent previous hospitalizations most likely had
little influence on our results [33]. We had access to
data on a large number of prospectively collected covari-
ates from databases with high validity for surgical proce-
dures, diagnosis codes, and laboratory data. Still, any
lack of specificity in routinely recorded data may have
reduced our ability to completely remove confounding
and most likely would attenuate our findings towards
the null. Severe confounding by socioeconomic differ-
ences between statin users and non-users is unlikely
given the tax-financed Danish public health care system
[53,54]. This is supported by a recent study that found
similar reduced risk of all-cause mortality among statin
users and non-users when comparing results from the
randomised 4S study with results from an observational
study based on prescription data [55].
Statins may exert their potential beneficial effects by
improving immune dysfunction caused by critical illness.
Surrogate physiological measures of severity of illness
and inflammation, e.g. CRP and WBC count, may thus
be in the pathway between statin use and mortality and
do not fulfil the criteria for being confounding factors
[40,55]. We therefore did not adjust for physiological
measures, including laboratory data, in the analysis.
Conclusions
In this large cohort study, preadmission use of statins
was associated with reduced risk of death within 30 days
and one year in general ICU patients. The associations
seen could be a pharmacological effect of statin use;
however, it remains to be fully clarified whether differ-
ences in characteristics of statin users and non-users
may explain at least part of the associations found.
Key messages
￿ In experimental studies statins have shown to have
anti-inflammatory, anti-thrombotic and immuno-
modulating effects independent of lowering lipids,
which may reduce mortality from critical illness.
￿ In observational studies statin use has been asso-
ciated with reduced mortality following major sur-
gery and severe infections.
￿ We found that preadmission statin use is asso-
ciated with reduced short- and long-term mortality
following intensive care.
￿ The beneficial effects may be most pronounced for
users of simvastatin.
Additional file 1: International Classification of Diseases (ICD) and
Anatomical Therapeutic Chemical (ATC) codes. Word document
containing ICD and ATC codes for diagnoses and drugs included in the
analyses of the current study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/cc8902-S1.DOC]
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